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Abstract 
Background: Specific anti‑phospholipids antibodies (aPLs) are used as classification criteria of the antiphospholipid 
syndrome (APS). These aPLs, although essential for diagnosis, do not predict disease phenotypes, which may require 
specific therapies. Non‑criteria aPLs are rarely evaluated and their role is yet to be defined. In the current study, we 
aimed to examine the association between criteria and non‑criteria aPLs and APS phenotypes.
Methods: Serum samples from 188 subjects, 130 APS patients and 58 controls were analyzed for the presence of 20 
aPLs (IgG and IgM isotypes to cardiolipin (CL), beta2‑glycoprotein1 (β2GP1), phosphatidic acid (P‑acid), phosphatidyl‑
choline (PC), phosphatidylethanolamine (PE), phosphatidylglycerol (PG), phosphatidylinositol (PI), phosphatidylserine 
(PS), annexin‑5 (AN) and prothrombin (PT) using a line immunoassay (GA Generic Assays, Germany). Sero‑positivity to 
the different aPLs/aPLs profiles was correlated to APS phenotypes (i.e. arterial thrombosis, CNS manifestations, venous 
thrombosis, relapsing disease, obstetric morbidity).
Results: In this cohort, arterial thrombosis was associated with accumulative number of ≥ 7/20 aPLs evaluated (OR 
4.1; CI 95% 1.9–96, p = 0.001) as well as the sole presence of aPT (IgG) (OR 2.3;CI 95% 1.1–5.1, p = 0.03). CNS manifes‑
tations were linked with a profile of 4 aPLs (IgG): aPT, aPG, aPI and aAN (OR 2.6;CI 95% 1.1–6.3, p = 0.03). Symptom‑
free period of ≥ 3 years was linked with lower number of aPLs and the presence of aPI (IgG) (OR 3.0;CI 95% 1.08–8.1, 
p < 0.05) or aAN (IgG) (OR 3.4;CI 95% 1.08–10.9, p < 0.05). APS related pregnancy morbidity correlated with a profile 
of 2 aPLs (IgG): aCL and aPS (OR 2.9; CI 95% 1.3–6.5, p < 0.05) or the sole presence of aAN (IgG) (OR 2.8; CI 95% 1.02–8, 
p = 0.05).
Conclusion: In this study, we observed an association between specific criteria/non‑criteria aPLs or aPLs profiles and 
clinical phenotypes of APS. Our data suggest that examination of a wider variety of aPLs may allow better characteri‑
zation of APS.
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Phosphatidic acid, Anti‑phosphatidylcholine, Anti‑phosphatidylethanolamine, Anti‑phosphatidylglycerol, Anti‑
phosphatidylinositol, Anti‑phosphatidylserine, Anti‑annexin 5, Phenotypes
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Background
The antiphospholipid syndrome (APS) is an acquired 
autoimmune disorder characterized by thrombotic 
events, obstetric morbidity and a myriad of systemic 
manifestations induced by the persistent presence of 
autoantibodies directed at phospholipids or phospho-
lipid-binding proteins (aPLs) [1–4] APS classification cri-
teria, defined in 2006, are currently in use, although their 
role for diagnosis or assessment of specific APS-related 
manifestations is less clear [6, 7]. Nevertheless, in the 
last decade, the significance of aPL persistency and accu-
mulation (i.e. the co-presence of criteria aPLs: anti-car-
diolipin (aCL), anti-beta2-glycoprotein1 (aβ2GP1) of the 
IgG or IgM subtypes and circulating lupus anticoagulant 
(LAC)) was established, particularly regarding the risk of 
APS evolvement. Moreover, sero-positivity of all three-
classification criteria-aPLs termed the “triple positive”-
variant is linked with a more aggressive disease [8–10]. 
The latter may require specific therapeutic interventions 
such as enhanced anti-coagulations or addition of other 
treatment modalities [8, 11–15]. In contrast transient 
appearance of aPLs during acute thrombosis or infections 
may not require intervention.
aPLs encompass also a spectrum of non-criteria aPLs 
which are typically not evaluated [4, 16]. Currently more 
than 30 different aPLs have been defined some of which 
bind directly to negatively charged phospholipids (e.g. 
phosphatidylinositol, phosphatidylserine) while others 
react with phospholipid binding proteins (e.g. distinct 
domains of β2GP1, prothrombin, annexin-V) [17–19]. 
The pathogenic role of non-criteria aPLs as well as their 
importance in defining APS phenotypes is yet to be 
revealed. Nevertheless, such roles were described for 
some non-criteria aPLs, for instance anti-phosphatidy-
lethanolamine (aPE) and anti-phosphatidylserine (aPS) 
with recurrent pregnancy losses [17–21] or anti-phos-
phatidylserine/prothrombin (aPS/PT) with thrombosis 
[21]. Notably, inconsistencies regarding criteria and non-
criteria aPLs have been reported [16] and most studies 
evaluated a single or a few non-criteria aPLs, frequently 
using different diagnostic platforms, which may be diffi-
cult to compare. Lately, a new technique for aPLs testing 
was developed, using a line immunoassay (LIA), a multi-
plex method that permits estimation of a relatively large 
profile of aPLs concomitantly [6, 22]. This novel assay 
technique appears to discriminate aPLs associated with 
APS from aPLs detected during infectious diseases and 
even asymptomatic carriers and may detect specific bind-
ing of aβ2GP1 to domain1 (D1) of the β2GP1 [16, 23–25].
Hence, in the current study we evaluated the presence 
of 20 criteria and non-criteria aPLs amid a cohort of well-
defined APS patients and the relationships between aPLs 
sero-positivity and clinical phenotypes of disease.
Patients and methods
Patients
In this case–control multicenter study, we evaluated 
serum samples from 130 APS patients and 58 geographi-
cally matched controls including 40 healthy individuals 
and 18 patients diagnosed with sepsis that may induce 
aPLs positivity transiently. Serum samples were stored 
at − 70  °C prior to their analysis. Diagnosis of APS was 
defined by the treating specialists, according to the APS 
classification criteria [5]. Data regarding prior aPL serol-
ogy (e.g. lupus anti coagulants detected according to 
international guidelines, and anti-cardiolipin and anti 
B2GPI antibodies detected by different methods than line 
blot), APS clinical manifestations/phenotypes as arterial 
thrombosis, CNS manifestations, venous thrombosis, 
latency period from last thrombotic events, pregnancy 
morbidity as well as age, gender and other concomitant 
autoimmune diseases (i.e. primary or secondary APS) 
were collected from medical files prior to inclusion in 
this study and analyzed respectively. The study received 
approval by the ethics committee (Sheba medical center 
nu. 4784) and fulfilled the ethical guidelines of the decla-
ration of Helsinki (Edinburgh 2000).
Methods
We analyzed all sera samples for the presence of 20 dif-
ferent aPLs of the IgG and IgM isotypes directed at 10 
antigens namely: cardiolipin (CL), beta-2 glycoprotein1 
(β2GP1), phosphatidic acid (P-acid), phosphatidylcholine 
(PC), phosphatidylethanolamine (PE), phosphatidylglyc-
erol (PG), phosphatidylinositol (PI), phosphatidylserine 
(PS), annexin 5 (AN) and prothrombin (PT) using a LIA 
(GA Generic Assays, Germany), as previously described 
[22, 25]. Briefly, the LIA strip is a hydrophobic membrane 
(polyvinylidenedifluoride, serving as a solid phase) that 
contains 11 lines: 10 with different APS-related autoan-
tigenic targets and one for the positive control. Each 
strip was manually positioned in diluted sera according 
to the manufacturer’s instructions. Following aPL bind-
ing to the target antigen on the solid-phase membrane, 
it underwent 30 min of washing in room temperature. In 
the second step, anti-human antibodies, conjugated with 
horseradish peroxidase were added for 15  min of incu-
bation followed by an additional washing step. Once the 
horseradish peroxidase converted the colorless substrate 
into purple, the strips were densitometrically analyzed 
utilizing a scanner and data interpreted by a software 
supplied by the manufacturer (GA Generic Assays, Ger-
many). The latter provides results on a scale of 0 to (+ 3) 
and consider positive reactivity for ≥ (+ 1) defined by the 
99%. As this method was recently developed, and dif-
ferences between populations have been reported, we 
assessed positivity in our cohort also according to the 
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analysis of healthy subjects in our population. Hence we 
considered positive only titers levels detected in less or 
equal to 5% of our healthy control group. Hence, 7 aPLs 
namely: aPG IgG, aPI IgG, aCL IgM, aPE IgM, aPI IgM, 
aPG IgM and aβ2GP1 IgM were considered positive if 
they were higher or equal to (+ 1) while the others were 
considered positive if the levels were higher or equal to 
(+ 2). LAC positivity was determined as recorded in the 
medical files, and was defined prior to initiation of treat-
ment with warfarin.
Statistical methods
The collected data was transferred and processed using 
Microsoft excel version 2007 (Microsoft Corp, Seat-
tle WA) and JMP version 7.0 (SAS institute, Cary, NC, 
USA). The statistical program SPSS 13.0 (SPSS, Chicago, 
IL, USA) was used for statistical analysis. For comparison 
between groups as well as correlations with clinical mani-
festations, we used the Fisher’s exact test, student’s T-test 
and Pearson Chi Square as appropriate. Values of p less 
than 0.05 were regarded statistically significant.
Results
We studied 130 APS patients and 58 controls, of which 40 
were healthy subjects and 18 disease controls diagnosed 
with sepsis. In our cohort of APS, patients’ prior serology 
was noticeable for LAC detected in 84% and “triple posi-
tivity” (i.e. sero-positivity for aCL and a β2GP1 and LAC) 
in 55% of patients (Table 1). Clinical and serological data 
obtained from medical files prior to inclusion in this 
study were collected and analyzed, respectively (Table 1).
Prevalence of aPLs among APS patients and controls
In this study, the sensitivity of the LIA including all aPLs 
of both IgM and IgG isotypes was 83% (49% for the IgM, 
and 69% for the IgG isotype). Regarding non-criteria 
aPLs, the specificity of the test was 100% for the IgM 
isotype and 95% for the IgG antibodies compared to 
healthy controls. aPLs were more prevalent among APS 
patients compared to our entire control groups as well 
as the healthy and diseased control subjects with sepsis 
separately (Table  2). Among controls, some aPLs were 
numerically more prevalent in the subgroup of patients 
suffering from sepsis compared to healthy controls, 
whereas a statistical significance was reached only for 
aβ2GP1 IgG detected in 1/40 (2.5%) healthy controls vs. 
4/18 (22.2%) septic patients (p = 0.03).
aPLs antibodies/profiles and phenotypes of APS
We analyzed the interactions of each aPL as well as dif-
ferent combinations of aPLs (profiles) with the follow-
ing clinical phenotypes of APS: arterial thrombosis, CNS 
manifestations, venous thrombosis, latency period from 
last thrombotic event and pregnancy morbidity (e.g. 
recurrent early abortion, premature delivery etc.) as sum-
marized in Table  3. In addition, we correlated serology 
with demographics (i.e. age, gender) and the presence of 
other autoimmune diseases, which in the vast majority of 
cases was systemic lupus erythematosus (i.e. primary or 
secondary APS).
Arterial thrombosis was associated with accumulation 
of any 7 or more of the 20 aPLs evaluated in this study 
compared to the presence of 6 or less (odds ratio [OR] 
4.1; confidence interval [CI] 95% 1.9–96, p = 0.001) and 
the sole presence of aPT IgG (OR 2.3 (CI 95% 1.1–5.1, 
p = 0.03). Patients diagnosed with primary APS were 
more prone to suffer from arterial thrombotic events 
compared to those with secondary APS (OR 2.2; CI 95% 
1.1–4.5, p = 0.03).
Table 1 Description of study cohort
Data retrieved from medical files
APS antiphospholipid antibody syndrome, CNS central nervous system, NA not applicable, aCL antibody to cardiolipin, aβ2GP1 antibody to beta2-glycoprotein1, LAC 
lupus anticoagulant
Clinical and serological manifestations APS patients (n = 130) All controls (n = 58) Healthy controls 
N = 40
Sepsis control 
n = 18
Age (years ± SD) 43.8 ± 13.2 37.7 ± 10.7 37 ± 11.7 39 ± 9
Gender (Female) 79.2% 66% 80% 30%
Time from diagnosis (years ± SD) 8.3 ± 7.4 NA
Secondary APS 51.5% NA
Arterial thrombosis 47.7% NA
CNS manifestations 35.4% NA
Venous thrombosis 59.2% NA
Pregnancy morbidity 29.2% NA
(LAC) positivity 84.0% NA
Triple positive (aCL + aβ2GP1 + LAC) 55.0% NA
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CNS manifestations correlated with the co-presence 
of a specific profile of four aPLs: aPT, aPG, aPI and aAN 
of the IgG isotype (OR 2.6; CI 95% 1.1–6.3, p = 0.03).
Venous thrombosis was present among our well-
defined APS cohort in 77/130 patients of which 
72(93%) were sero-positive for at least one aPL tested 
herein. Notably, the presence of aPLs was highly 
associated with venous thrombosis in general, namely 
while comparing APS patients to our control groups, 
72/77 patients with venous thrombosis were sero-pos-
itive for at least 1 aPL (either IgG or IgM) whereas only 
7/40 healthy control or 16/58 healthy and sepsis control 
were positive (p < 0.001 for both comparisons respec-
tively). Among our APS patients, venous thrombosis 
Table 2 Prevalence of different anti-phospholipid antibodies (aPLs) among patients with the antiphospholipid syndrome 
(APS) and controls
HC healthy controls, SP sepsis patients, CL cardiolipin, β2GP1 beta2-glycoprotein1, P-acid phosphatidic acid, PC phosphatidylcholine, PE phosphatidylethanolamine, 
PG phosphatidylglycerol, PI phosphatidylinositol, AN annexin 5, PS phosphatidylserine, PT prothrombin, NS non-significant
APLs APS patients
N = 130
All controls
N = 58
p value
APS vs All controls
Healthy controls (HC)
N = 40
p value
APS vs HC
Sepsis patients (SP)
N = 18
p value
APS vs SP
CL IgM 34 (26%) 1 (2%) 0.001 0 < 0.001 1 (5%) 0.07
IgG 77 (59%) 1 (2%) 0.001 0 < 0.001 1 (5%) < 0.001
P‑acid IgM 17 (13%) 0 0.001 0 < 0.05 0 NS
IgG 73 (56%) 0 0.001 0 < 0.001 0 < 0.001
PE IgM 4 (3%) 0 NS 0 NS 0 NS
IgG 3 (2%) 0 NS 0 NS 0 NS
PG IgM 4 (3%) 0 NS 0 NS 0 NS
IgG 50 (38%) 0 0.001 0 < 0.001 0 < 0.001
PI IgM 11 (8%) 0 0.01 0 0.06 0 NS
IgG 59 (45%) 1 (2%) 0.001 1 (2%) < 0.001 0 < 0.001
PS IgM 16 (12%) 0 0.003 0 < 0.05 0 NS
IgG 73 (56%) 0 0.001 0 < 0.001 0 < 0.001
AN IgM 2 (1%) 1 (2%) NS 0 NS 1 (5%) NS
IgG 36 (27%) 5 (9%) 0.003 2 (5%) < 0.01 3 (16%) NS
β2GP1 IgM 42 (32%) 6 (10%) 0.003 4 (10%) < 0.001 2 (10%) NS
IgG 86 (66%) 5 (9%) 0.001 1 (2%) < 0.001 4 (22%) < 0.001
PT IgM 2 (1%) 0 NS 0 NS 0 NS
IgG 40 (30%) 1 (2%) 0.001 0 < 0.001 1 (5%) < 0.05
Table 3 APS phenotypes correlation with aPLs and aPLs profiles
Data is compared among APS patients with and without the defining phenotype
a CL cardiolipin, β2GP1 beta2-glycoprotein1, P-acid phosphatidic acid, PC phosphatidylcholine, PE phosphatidylethanolamine, PG phosphatidylglycerol, PI 
phosphatidylinositol, AN annexin 5, PS phosphatidylserine, PT prothrombin
APS phenotypes Associated aPLs and clinical manifestations O.R.
Arterial thrombosis > 7 any  aPLsa 4.1 [CI 95% 1.9–96]
aPT IgG 2.3 [CI 95% 1.1–5.1]
Primary APS 2.2 [CI 95% 1.1–4.5]
CNS manifestations aPT + aPG + aPI and aAN (IgG) 2.6 [CI 95% 1.1–6.3]
Venous thrombosis aP‑acid IgM 0.3 [CI 95% 0.1–0.9]
Event free period > 3 years from last thrombotic events aPI IgG 3 [CI 95% 1.08–8.1]
aAN IgG 3.4 [CI 95%1.08–10.9]
Pregnancy morbidity aCL IgG and aPS IgG 2.9 [CI 95% 1.3–6.5]
anti‑AN IgG 2.8 [CI 95% 1.02–8]
Arterial thrombosis 3.3 [CI 95% 1.5–7.2]
CNS manifestations 3.9 [CI 95% 1.7–9]
Secondary APS 2.3 [CI 95%1.03–5.16]
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as a phenotype was not linked to any specific aPL, but 
rather an inverse correlation was found between this 
phenotype and aP-acid IgM (OR 0.3; CI 95% 0.1–0.9, 
p = 0.02).
Latency from last thrombotic events The time range 
from last thrombotic event in our cohort was 0.5 to 
16  years with an average of 4.8  years. Event-free period 
(i.e. with no recurrence of thrombotic events) of more 
than 3  years was significantly associated with sero-
positivity to either aPI IgG or aAN IgG (OR 3; CI 95% 
1.08–8.1, p < 0.05 and OR 3.4; CI 95% 1.08–10.9, p < 0.05, 
respectively), as well as with a lower cumulative number 
of aPLs (7.6 ± 6 vs. 11 ± 6, p < 0.05) compared to patients 
that experienced recurrent thrombosis within this time.
Pregnancy morbidity was observed in 38/103 (37%) of 
female APS patients. A profile of 2 aPLs: aCL IgG and 
aPS IgG was linked with this phenotype (OR 2.9; CI 95% 
1.3–6.5, p < 0.05) as well as the sole positivity of anti-AN 
IgG (OR 2.8; CI 95% 1.02–8, p = 0.05). Notably, APS-
related pregnancy morbidity was also linked to arterial 
thrombosis (OR 3.3; CI 95% 1.5–7.2, p = 0.004), CNS 
morbidity (OR 3.9; CI 95% 1.7–9, p = 0.001), and second-
ary APS (OR 2.3; CI 95% 1.03–5.16, p = 0.04).
Older age allied with the presence of aP-acid IgM 
(51 y/o or older; p = 0.001) as well as with the profile of 
aβ2GP1 IgM and aCL IgM (46 y/o or older; p = 0.03) 
compared to sero-negative patients to these specific 
antibodies.
Gender was linked with specific aPLs: male with aCL 
IgG, aPG IgG, aPI IgG, aAN IgG and aPT IgG and female 
with aPE IgM (Table 4).
Concomitant autoimmune diseases 67/130 (51.5%) of 
our APS cohort had a concomitant autoimmune disease, 
which in the vast majority was systemic lupus erythema-
tosus, defining secondary APS. In comparison to primary 
APS, secondary disease correlated with the presence of 
aβ2GP1 IgG (OR 3.9; CI 95%:1.8–8.2, p = 0.04).
Interactions between different aPLs
In the current study we observed interactions between 
most aPLs, as the presence of each aPL was statistically 
associated with sero-positivity of other aPLs of the same 
isotype (IgG or IgM; data not shown). An exception was 
noted for aPE of IgM isotype which was linked only with 
aβ2GP1 IgM (p < 0.05) and not with all other aPLs. Inter-
estingly, the presence of LAC correlated with aPLs of the 
IgG subtype directed at CL, P-acid, PG, PI, PS, β2GP1, 
and PT (p < 0.05).
Discussion
In this study we evaluated 20 “criteria” and “non-criteria” 
aPLs targeted at 10 different phospholipids or phospho-
lipid-binding proteins in a cohort of well-defined “highly 
active serologically” APS patients (i.e. 84% were LAC pos-
itive and 55% “triple positive”) aiming to correlate these 
aPLs with clinical phenotypes of APS.
APS is a unique acquired thrombotic condition, 
which causes both arterial and venous thrombosis that 
may reoccur despite anti-coagulation therapy. Arterial 
and recurrent thrombosis are both considered to have 
a worse outcome, thus are usually followed by a more 
forceful therapy [9, 26]. Herein, we found that certain 
aPLs and/or aPLs profiles are associated with three APS 
thrombotic phenotypes: arterial thrombosis, CNS mani-
festations and recurrent thrombosis. Arterial thrombosis 
linked with the presence of any 7 or more aPLs compared 
to 6 or less. This stands in agreement with the notion that 
aPLs accumulation is an adverse marker of APS. The lat-
ter was put forward in 2007 by Bizzaro. et al. [27] and in 
2011 by Pengo. et  al. [28] defining “triple positivity” as 
a risk factor for thrombosis. Later on Otomo. et  al. [9] 
evaluated criteria (aCL, aβ2GP1) and non-criteria (aPS/
PT complex) aPLs documented aPLs accumulation as a 
prognostic factor, so did Cervera R. et al. [29] that dem-
onstrated “non-criteria” aPLs (aPT, aPE, anti-vimentin 
etc.,) relation to disease severity.
Additionally, we found a tie between arterial thrombo-
sis and the existence of aPT. The thrombotic-predictive 
value of aPT was formerly suggested in a 15 year longitu-
dinal study of SLE patients [27] as well as in a prospective 
study conducted by Forastiero  et al. [30]. Lately Zhang 
et al. [31] found, similar to our data, that aPT relates to 
arterial thrombosis. In contrast, a review of 11 studies 
including 1440 patients concluded that aPT assessment 
was non-contributory for routine APS laboratory work-
out [32]. These contradicting conclusions may result 
from different methods used for detection of aPT or dif-
ferent cohorts of patients assessed. But perhaps the most 
striking difference is the role looked at as for routine 
APS workout aPT appears to render no benefit while a 
Table 4 Gender association with  anti-phospholipids 
antibodies (aPLs) among  patients with  the  anti-
phospholipids syndrome (APS)
PE phosphatidylethanolamine, CL cardiolipin, PG phosphatidylglycerol, PI 
phosphatidylinositol, AN annexin 5, PT prothrombin
APLs associated 
with gender
Odds ratio (CI 95%) 
for female sex
Odds ratio (CI 
95%) for male 
sex
aPE IgM 2.5 (1.03–6) 0.39 (0.16–0.96)
aCL IgG 0.3 (0.1–0.6) 3.4 (1.6–7.4)
aPG IgG 0.2 (0.1–0.5) 2.2 (1–4.6)
aPI IgG 0.2 (0.1–0.5) 2.5 (1.1–5.4)
aAN IgG 0.2 (0.1–0.4) 3.0 (1.3–6.9)
aPT IgG 0.1 (0.4–0.3) 3.8 (1.7–8.5)
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plausible role for risk stratification and phenotyping of 
“well-defined” APS and SLE patients may be suggested.
APS commonly affects the central nervous system 
(CNS) manifesting as stroke, seizures, dementia, cogni-
tive dysfunction, chorea, migraine, psychosis, demyelina-
tion etc. [4, 33]. In this study, for the first time to the best 
of our knowledge, an association between APS-related 
CNS manifestations and a specific profile of four aPLs 
namely the co-presence of aPT aPG, aPI and aAN of the 
IgG isotype was observed, of which, like aPT also aAN 
and aPI were interrelated with thrombosis [34]. Annex-
ins are a group of 12 regulatory proteins that are involved 
in vesicle trafficking, calcium signaling, cell growth, divi-
sion, and apoptosis. Annexin 2 and 5 have an affinity to 
phospholipids, and antibodies directed at these proteins 
were found in patients with either arterial or venous 
thrombosis. Likewise, anti-phosphatidylinositol antibod-
ies were significantly associated with thrombosis among 
APS and SLE patients [35].
One of the most difficult phenotypes of APS is the 
‘recurrent thrombosis’ one. Approximately 20% of 
APS patients will experience recurrence within 3.4 to 
16.3 years, depending on their treatments with antiplate-
let, anticoagulant, or a combination of these therapies 
[36]. Currently, there are no established risk factors for 
‘the thrombotic recurrence phenotype’ though the plau-
sible role of aPLs has been suggested, and may eventually 
allude to enhanced therapy for patients at risk [37–39]. 
Herein, we found that a low recurrence rate, defined as 
thrombosis free period of more than 3 years, links with 
a lower accumulative number of aPLs, further support-
ing the perception that more aPLs allied with a worst 
outcome.
APS is the most frequently acquired risk factor for 
recurrent pregnancy losses, ischemic placental dysfunc-
tion, fetal growth restriction, preeclampsia, premature 
birth and intrauterine death [14, 40]. Apart from the 
thrombotic variants of APS, obstetric APS (OAPS) is 
probably the most common phenotype. Obstetric mor-
bidity may be the only presentation of APS or may co-
exist with thrombotic and non-thrombotic phenotypes 
[41]. In the current study, we found that obstetric mor-
bidity was linked with CNS and arterial thrombotic phe-
notypes, which stands in agreement with other reports 
such as a recent study by Gris et  al. [42] documenting 
OAPS association with mental disorders. Besides, we 
found OAPS to be linked with a profile of two aPLs: aCL 
and aPS or the sole presence of aAN of the IgG isotype. 
Recently, aCL was found to be the most common aPL 
present in a large cohort of 750 pregnancies [43]. Equally, 
aPS was linked with OAPS in several studies and in par-
ticular, monoclonal aPS antibodies were found to reduce 
yolk sac growth in animal models as well as placental 
trophoblastic cell growth and proliferation in humans 
[44]. In contrast to aCL and aPS, the role of aAN in OAPS 
is yet controversial. The latter was linked with recurrent 
pregnancy morbidity and losses in some studies [35, 45] 
but this association was not ascertained in others [41, 
46, 47]. Still, the prediction of aPL related pregnancy 
morbidity is an issue of great debate, especially among 
women defined as “only aPLs carriers” or those with less 
than three early miscarriages. Thus, although our results 
require further studies, the idea that certain aPLs or aPLs 
profile may be used as a marker of pregnancy morbidity 
is intriguing.
There is a strong link between aPLs and venous throm-
bosis as was described in numerous studies as well as the 
current one while comparing APS patients to healthy 
subjects and patients diagnosed with sepsis. However, 
none of the aPLs studied herein was specifically linked 
with venous thrombosis among APS patients. In other 
words the vast majority of patients with venous thrombo-
sis were aPL sero-positive and no differences were docu-
mented compared to APS patients that did no exhibit 
venous thrombosis. In contrast, a striking observation in 
this study was the inverse association of anti P-acid anti-
body of the IgM isotype with venous thrombosis. The 
anti P-acid antibody was rarely studied as a single anti-
body and for the best of our knowledge this is the first 
report of such inverse association. Of note anti P-acid 
was linked with thrombosis in several studies which eval-
uated mostly IgG antibodies and regarded thrombosis 
in general both arterial and venous. In a recent study of 
sero-negative APS patients, anti P-acid was linked with 
fetal losses and not with thrombosis [48]. Further studies 
are required to verify such an inverse correlation. Inter-
estingly in this study the anti-P-acid IgM, as well as other 
IgM antibodies were linked with older age.
Last but not least, from the diagnostic perspective, 
the LIA was easy, efficient and with good sensitivity and 
specificity while employing cutoffs ascertained by healthy 
controls. This method enabled the discrimination of aPL 
found in APS patients from those in asymptomatic car-
riers as reported previously [24]. Within our controls, 
some aPLs were numerically more prevalent among sep-
tic control patients compared to healthy subjects, but a 
significant difference was observed only for anti-β2GP1 
IgG. The latter transient appearance during infection was 
formerly reported [49, 50]. Furthermore, we observed 
interactions between different aPLs of the same iso-
type. Similar observations have been reported and led to 
the hypothesis that broad aPLs positivity may be due to 
epitope spreading [51].
Our study has several limitations, as our cohort 
included “serologically active” APS patients (84% were 
LAC positive and 55% triple positive) that fulfill the 
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criteria for APS, which could cast doubt on the impli-
cation of our results to patients with “lower serological 
activity” (e.g. single low titer aPL). A selection bias was 
inevitable as all patients had a least one clinical manifesta-
tion of APS to fulfill its classification criteria. Noteworthy, 
this study aimed to define subtypes of APS rather than 
use aPL for diagnosis or classification of disease. Addi-
tionally, aPLs were evaluated in this study using a single 
blood sample from each subject and a single method of 
detection. The former do not allow estimations of aPL 
profiles at the time of events, but rather a retrospective 
clinical correlation, as well as the lack of long term follow 
up, nor the role of other aPLs or aPL-complexes as anti-
PS/PT (only PS and PT separately) or anti-domain-1 of 
β 2GPI. The latter two aPL may add value to the assess-
ment of APS patients requiring further studies. Using 
multiple comparative methods for detection of aPLs is 
of significance, hence the use of the line dot blot (LIA) 
semi quantitative method as a single method is a limita-
tion. However, all patients included in this study were 
originally criteria aPL positive and recently Thaler et al. 
demonstrated similar results for detection of non-criteria 
aPL by the LIA method compared to ELISA [52]. Thus, 
we assume that there will be no significant differences by 
ELISA to our results by LIA. Moreover, Thaler et al [52] 
reported a higher sensitivity of the LIA technique for aPL 
recognizing anionic phospholipids. Lastly, the aim of our 
study was to evaluate APS profiles, therefore correlation 
with a single criteria or non-criteria manifestation (e.g. 
intra uterine fetal death of thrombocytopenia) was not 
evaluated.
Conclusions
Herein, we report that criteria and non-criteria aPLs and/
or aPLs profiles are statistically linked with APS pheno-
types such as arterial thrombosis, CNS manifestations, 
recurrent thrombosis and obstetric APS. Additionally, 
we found that accumulation of these aPLs is associated 
with more severe variants of diseases namely arterial and 
recurrent thrombosis. Our data suggest that evaluating a 
broad spectrum of aPLs may enable defining APS pheno-
types and, thus, may have a future role in precision choice 
of therapy for this autoimmune multifaceted disease.
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